US 100% pharmaceutical tariff

•  

1.What Is the US 100% Pharmaceutical Tariff & Core Policy Framework

1.1 Legal Basis & Effective Timeline

On April 2, 2026, President Trump signed an executive order under Section 232 of the Trade Expansion Act of 1962, imposing a 100% ad valorem tariff on imported patented drugs and APIs for countries without special agreements.

 

• • Large enterprises: 120‑day grace period

• • Small enterprises: 180‑day grace period

• • Long-term exemption available for firms signing pricing commitments and US manufacturing commitments

1.2 Scope & Exemptions
The tariff is not universal, which is critical for global medical trade:

 

• • Covered: patented branded drugs, patented APIs, high‑value intermediates

 

• • Exempt: generic drugs, non‑patented raw materials, orphan drugs, animal health products, most routine medical devices and consumables

This structure means the US 100% pharmaceutical tariff primarily pressures innovative drugmakers while leaving room for suppliers of generics, medical devices, and consumables.

1.3 Why the US Is Forcing Pharma Factories to Relocate

1.National health security: Over 50% of US patented drugs are imported; domestic API production is only about 15%

2.Reduce patient costs: Pressure foreign firms to lower prices or produce locally

3.Revitalize manufacturing: Create jobs and strengthen industrial base

4.Reduce reliance on global supply chains amid geopolitical tensions

The tariff acts as a strong incentive: either move production to the US or face doubled import costs.

2.Multidimensional Impacts of the Tariff Policy

2.1 Impact on Global Pharmaceutical Companies

 

• • European, Japanese, Korean drugmakers: capped at 15% under trade agreements; many plan US investment

• • Non‑aligned manufacturers: face 100% tariff, forcing rapid restructuring

• • Short‑term: price hikes, supply chain disruptions, project delays

• • Long‑term: regionalization of R&D and production, “China + 1” or “US + 1” strategies

2.2 Impact on US Healthcare System

 

• • Higher prices for patented drugs in the short run

• • Potential shortages as imports adjust

• • Downward pressure on prices in 2–3 years as local production expands

• • Increased demand for affordable alternatives, benefiting generic and device suppliers

2.3 Impact on Global Supply Chains & Logistics

 

• • Accelerated shift from globalized to regionalized supply chains

• • Increased nearshoring and friend‑shoring

• • Logistics costs and lead times rise

• • Demand for stable, cost‑effective Asian suppliers increases

2.4 Balanced View: Is the Tariff Effective?

Arguments supporting the policy:

 

• • Improves medical supply security

• • Creates domestic manufacturing jobs

• • Lowers long‑term drug costs

Arguments questioning the policy:

 

• • High implementation cost; new FDA‑compliant plants take 5–8 years

• • May raise inflation and healthcare spending

• • Disrupts long‑established global division of labor

The real effect will unfold gradually over the next 2–5 years.

3. Opportunities & Challenges for China’s Medical Products Under the Tariff

3.1 Overall Impact Structure

The US 100% pharmaceutical tariff creates a two‑track effect for China’s medical exports:

 

• • Negative: patented drugs, high‑end innovative APIs face higher barriers

• • Positive: medical devices, hospital beds, wheelchairs, orthopedic braces, consumables, and generics are mostly exempt and gain price competitiveness

3.2 Major Opportunities

 

1. 1. Medical device advantage expandsMost devices are outside the tariff scope. As Western manufacturers face cost and capacity pressure, global buyers increasingly choose Chinese equipment.

1. 1. Stable supply chain advantageChina has complete industrial chains, stable output, and fast delivery. In a volatile global market, reliability becomes a core competitive advantage.

1. 1. Benefit from supply chain diversionAs drugmakers restructure, CDMO and contract manufacturing demand rises, supporting related device and consumable exports.

1. 1. Middle East, Southeast Asia, Latin America growthThese regions expand imports of Chinese hospital beds, electric wheelchairs, orthopedic supports, and consumables amid US market uncertainty.

3.3 Challenges to Address

 

• • Compliance requirements in North America and Europe

• • Need for strengthened certification and traceability

• • Competition from Mexico, Eastern Europe, and Southeast Asia

• • Fluctuating logistics and customs clearanc

Overall, the period following the US 100% pharmaceutical tariff is a strategic window for China’s medical device industry.

4. How China‑Made Medical Products Gain Advantage in the Global Market

4.1 Product Categories That Benefit Most

 

• • Hospital beds: manual, electric, ICU, long‑term care beds

• • Electric wheelchairs: portable, folding, heavy‑duty models

• • Orthopedic braces & supports: spine, knee, ankle, rehabilitation devices

• • Medical consumables: disposable supplies, wound care, clinical accessories

These lines are exempt from the 100% tariff and enjoy stable global demand.

4.2 Core Competitive Strengths

 

1. 1. Integrated manufacturingFull industrial chain from raw materials to assembly ensures consistency and cost efficiency.

1. 1. Quality & certificationISO, FDA, CE compliance supports global market access.

1. 1. Stable deliveryMature logistics and inventory systems reduce supply disruption risk.

1. 1. Cost performanceAffordable without compromising safety or durability

4.3 Global Market Demand Growth

 

• • Aging populations drive long‑term care equipment

• • Post‑pandemic focus on public health resilience

• • Hospital expansion in emerging markets

• • Preference for stable, non‑geopolitically sensitive suppliers

5. Jingze Medical: Your Stable Partner in the Tariff Era

Against the background of the US 100% pharmaceutical tariff and supply chain restructuring, Jingze Medical provides reliable, compliant, and price‑stable solutions for global buyers.

5.1 Core Product Lines

 

• • Hospital Beds: ICU, electric, manual, long‑term care beds

• • Electric Wheelchairs: lightweight, folding, outdoor, pediatric

• • Orthopedic Braces: spinal, knee, ankle, post‑op rehabilitation

• • Medical Consumables: disposable supplies, clinical accessories

5.2 Strengths for Global Partners

 

• • Strict quality control for safety and durability

• • Fast global delivery with secure packaging

• • Professional after‑sales and warranty

• • Integrated production ensuring stable capacity

Jingze Medical helps you maintain stable supply amid trade changes.

Learn more：https://jingzemedica.com/

5.3 How We Help You Navigate Tariff Uncertainty

 

• • Product classification and tariff compliance review

• • Flexible order and logistics planning

• • Multi‑region inventory and delivery options

• • Continuous certification upgrades for major markets

Stable supply = stable business.

6. Strategic Suggestions for Importers & Distributors

 

1. 1. Diversify supply sources to reduce single‑region risk

1. 1. Prioritize tariff‑exempt categories such as hospital beds, wheelchairs, consumables

1. 1. Strengthen cooperation with certified Chinese manufacturers

1. 1. Optimize inventory to buffer logistics volatility

1. 1. Track policy updates to adjust ahead of schedule

The goal is to maintain cost, quality, and delivery stability.

7. Conclusion & Summary Analysis

The US 100% pharmaceutical tariff is more than a trade policy—it is a restructuring of the global medical and pharmaceutical system. By forcing production closer to home, the US aims to strengthen security and lower long‑term costs, but the transition brings short‑term disruption.
For China’s medical product exporters, the policy creates a differentiated landscape: pressure on patented drugs but clear opportunities for medical devices, hospital beds, electric wheelchairs, orthopedic braces, and consumables. With complete industrial chains, stable capacity, and strong cost performance, Chinese manufacturers are well‑positioned to gain global share.
In this new era, choosing a stable, professional partner like Jingze Medical ensures your supply chain remains resilient, compliant, and competitive.

For industry data and policy updates, please refer to:https://www.bbc.com/news/articles/cx29kke01gpo